Hookipa Pharma signs US$958 M Deal with Roche to develop HB-700 for KRAS-mutated Cancers

By Amit Kaushik

Pharma Deals Review: Vol 2022 Issue 11 (Table of Contents)

Published: 5 Nov-2022

DOI: 10.3833/pdr.v2022.i11.2745     ISSN: 1756-7874

Section: Licensing



Hookipa Pharma has announced a collaboration with Roche for the development and commercialisation of HB-700, a new investigational arenaviral immunotherapy for the treatment of KRAS-mutated cancers...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details